13D Filing: Birchview Capital and Yield10 Bioscience Inc. (YTEN)

Page 11 of 12

Page 11 of 12 – SEC Filing

(d)        Except
as set forth in this Schedule 13D, to the knowledge of the Reporting Person, no person had the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of, securities covered by this Schedule 13D.

(e)        Not
applicable.

ITEM 7. Material to be Filed as Exhibits.
Exhibit 1 Underwriting Agreement, dated as of December 19, 2017, by and between Yield10 Bioscience, Inc. and Ladenburg Thalmann & Co. Inc. as representative of the several underwriters, if any, named on Schedule I thereto (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed by the Issuer with the SEC on December 21, 2017).
Exhibit 2 Form of Series A Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Issuer with the SEC on December 21, 2017).
Exhibit 3 Form of Series B Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed by the Issuer with the SEC on December 21, 2017).
(Page 11 of 12 Pages)

Follow Yield10 Bioscience Inc. (NASDAQ:YTEN)

Page 11 of 12